Hydroxyurea (Hydroxycarbamide; HU) is commonly used for the long-term treatment of patients with Philadelphia-chromosome negative chronic myeloproliferative neoplasms (MPNs). It is considered a first-choice agent for the treatment of these disorders as underlined by the European Leukemia Net Consensus Conference [1], although it is formally approved for this indication in some countries only. The drug is reportedly well tolerated in the large majority of subjects, although systemic and/or localized toxicities have been reported. Consensus criteria for definition of “intolerance” to HU have been described; patients who develop intolerance are candidate for second-line therapy and, more recently, for investigational drugs. However, no epidemiologic information about the occurrence of the most clinically significant HU-associated adverse events is yet available. In this study, the authors report on a multicenter series of 3,411 patients who were treated with HU among which 184, accounting for 5% of total, developed significant drug-related toxicities. These data provide an estimate of the frequency and a detailed characterization of clinically significant HU-related toxicities; these information have relevance for the management of MPN patients who require second-line therapy after developing HU-related intolerance.

Antonioli, E., Guglielmelli, P., Pieri, L., Finazzi, M., Rumi, E., Martinelli, V., et al. (2012). Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. AMERICAN JOURNAL OF HEMATOLOGY, 87(5), 552-554 [10.1002/ajh.23160].

Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN

FINAZZI, MARIA CHIARA;ELLI, ELENA MARIA;POGLIANI, ENRICO MARIA;
2012

Abstract

Hydroxyurea (Hydroxycarbamide; HU) is commonly used for the long-term treatment of patients with Philadelphia-chromosome negative chronic myeloproliferative neoplasms (MPNs). It is considered a first-choice agent for the treatment of these disorders as underlined by the European Leukemia Net Consensus Conference [1], although it is formally approved for this indication in some countries only. The drug is reportedly well tolerated in the large majority of subjects, although systemic and/or localized toxicities have been reported. Consensus criteria for definition of “intolerance” to HU have been described; patients who develop intolerance are candidate for second-line therapy and, more recently, for investigational drugs. However, no epidemiologic information about the occurrence of the most clinically significant HU-associated adverse events is yet available. In this study, the authors report on a multicenter series of 3,411 patients who were treated with HU among which 184, accounting for 5% of total, developed significant drug-related toxicities. These data provide an estimate of the frequency and a detailed characterization of clinically significant HU-related toxicities; these information have relevance for the management of MPN patients who require second-line therapy after developing HU-related intolerance.
Articolo in rivista - Articolo scientifico
Hydroxyurea,toxicity,Ph'-negative MPN,chronic myeloproliferative neoplasms
English
2012
87
5
552
554
none
Antonioli, E., Guglielmelli, P., Pieri, L., Finazzi, M., Rumi, E., Martinelli, V., et al. (2012). Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. AMERICAN JOURNAL OF HEMATOLOGY, 87(5), 552-554 [10.1002/ajh.23160].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/37241
Citazioni
  • Scopus 102
  • ???jsp.display-item.citation.isi??? 94
Social impact